Healthcare › Drug Manufacturers
Eli Lilly
- Ticker
- LLY
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Drug Manufacturers
Price data arrives in a later stage, so no price is shown yet.
Latest news
ImportantLLY
Explain this story: Lilly reports Foundayo data. Eli Lilly and Company stock costs EUR 1,021.90 ahead of results
Eli Lilly's oral GLP-1 medicine, Foundayo, demonstrated a 57.00% reduction in predicted 10-year type 2 diabetes risk and an 18.00% reduction in predicted cardiovascular disease risk after 72 weeks at a 17.2 mg dose. These findings, from post-hoc analyses of the ATTAIN-1 Phase 3 study, provide new data points for the company's oral obesity-medicine strategy. Investors are anticipating the third-quarter 2026 earnings call on October 29, 2026, to assess the continued growth of the company's revenue and the commercial adoption of its GLP-1 products.
OtherAD HOC NEWSSector and industry: HealthcareDrug ManufacturersTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
Eli Lilly's oral GLP-1 medicine, Foundayo, demonstrated a 57.00% reduction in predicted 10-year type 2 diabetes risk and an 18.00% reduction in predicted cardiovascular disease risk after 72 weeks at a 17.2 mg dose. These findings, from post-hoc analyses of the ATTAIN-1 Phase 3 study, provide new data points for the company's oral obesity-medicine strategy. Investors are anticipating the third-quarter 2026 earnings call on October 29, 2026, to assess the continued growth of the company's revenue and the commercial adoption of its GLP-1 products.
Company newsLLY
Explain this story: Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?
Viking Therapeutics' stock recently surged by 35% following promising maintenance dosing data for its GLP-1 drug candidate, VK2735. The drug showed high weight loss maintenance with reduced dosing frequency, positioning Viking as a potential competitor in the GLP-1 market currently dominated by Eli Lilly and Novo Nordisk. Investors are now evaluating if it's still a good time to invest in Viking, given the stock's volatility and the inherent risks of biotech investments, though future catalysts like regulatory approval could drive further growth.
OtherYahoo Finance
Company newsAMGN
Explain this story: Kailera Therapeutics (Nasdaq:KLRA) - Stock Analysis
Kailera Therapeutics (KLRA) is a clinical-stage biopharmaceutical company focused on developing therapies for obesity and related conditions. The company recently reported positive Phase 3 data for its oral GLP-1 receptor agonist KAI-7535, showing significant weight loss and HbA1c reductions. KLRA is preparing for global Phase 3 trials for its Ribupatide candidates and has appointed a new CTO, indicating late-stage development and commercialization efforts, despite current unprofitability and a short cash runway.
OtherSimply Wall StreetHealthcare
Company newsMRNA
Explain this story: Moderna Inc Stock (MRNA) Moved Up by 5.16% on Sep 22: A Full Analysis
Moderna Inc. (MRNA) saw its stock rise by 5.16% due to positive market reaction to strong Phase 3 oncology trial data for its personalized cancer therapy and regulatory clearances for updated COVID-19 vaccines. Despite this recent upward momentum and positive analyst upgrades, the company faces ongoing challenges such as operational cash burn, net losses, and potential equity dilution from recent convertible note issuances. Investors are keenly awaiting detailed Phase 3 data, which will be a critical catalyst to justify the stock's current valuation amidst existing risks and some analyst downgrades.
Other
Company newsAMGN
Explain this story: Amgen Inc Stock (AMGN) Moved Up by 3.90% on Sep 22: Facts Behind the Movement
Amgen Inc. (AMGN) stock rose by 3.90% on September 22, driven by positive Phase 3 clinical trial results for dazodalibep in Sjögren's disease, which met its primary endpoint. The company's diverse late-stage pipeline, including its obesity candidate MariTide and oncology treatment IMDELLTRA, also contributed to investor confidence. Despite technical indicators showing a neutral to sell signal, analysts maintain an average price target of $389.14 with a "Hold" rating.
OtherTradingKeySector and industry: Healthcare
Elsewhere
These links open other websites. We do not provide price data yet.